WallStSmart
MDLN

Medline Inc. Class A Common Stock

NASDAQ: MDLN · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES

$43.40
-1.90% today

Updated 2026-04-29

Market cap
$36.70B
P/E ratio
30.35
P/S ratio
1.29x
EPS (TTM)
$1.43
Dividend yield
—
52W range
$35 – $51
Volume
6.6M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Medline Inc. Class A Common Stock (MDLN) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$43.40
Consensus
$50,480.00
+116213.36%
2030 Target
$619.92
+1328.39%
DCF
$144.24
+68.77% MoS
28 analysts:
19 Buy3 Hold0 Sell

Management guidance

Medline provided 2026 guidance of organic sales growth of 8-9% and Adjusted EBITDA between $3.5B-$3.6B. Based on 2025 revenue of $28.43B, this implies 2026 revenue of approximately $30.7B-$31.0B. Management emphasized 'strengthened foundations for long-term growth' following IPO, with expansion of distribution network (new 1.2M sq ft facility in Texas operational Q2 2027) supporting sustained mid-single-digit organic growth trajectory.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$1,031.72
$41.9B Rev × 20x P/S
Base case (2030)
$619.92
$41.9B Rev × 12x P/S
Bear case (2030)
$411.80
$41.9B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$23.2B$25.5B$28.4B$31.5B$34.0B$36.6B$39.1B$41.9B
Revenue growth—9.8%11.5%10.9%7.7%7.7%7.1%7.1%
EPS——$0.69$1.49$1.68$1.90$2.12$2.38
P/S ratio———12.0x12.0x12.0x12.0x12.0x
Implied price———$464.94$500.36$540.22$580.07$619.92

Catalysts & risks

Growth catalysts
+ New 1.2M sq ft distribution center in Midlothian, TX operational Q2 2027 expanding next-day delivery to 95% of US customers
+ Pick Pack Pro automated fulfillment technology deployment driving operational efficiency and margin expansion
+ Prime vendor wins in senior living and healthcare segments indicating market share gains and recurring revenue growth
+ Post-IPO capital deployment for M&A and organic growth initiatives following $7.2B IPO in December 2025
Key risks
- Valuation risk: P/E of 31x significantly above peer/industry averages; stock trading near 52-week highs after insider selling at $41/share signals potential near-term correction
- Margin compression: Profit margin of 4.1% limits pricing power in competitive healthcare supplies market amid tariff and labor cost pressures
- Debt level: Total debt of $12.56B (LT Debt/Eq 1.20x) limits financial flexibility if growth decelerates or interest rates remain elevated

Methodology

Medline Inc. Class A Common Stock's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 28 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.